WEIHAI BANK (09677) plans to issue up to 150 million H shares to Jinlian Group at a premium of approximately 17.97%.
Weihai Bank (09677) announced that on December 21, 2025, the bank entered into an H-share subscription agreement with Jinlian Group, intending to issue up to 150 million H-shares to Jinlian Group at a subscription price of RMB 3.29 per share, representing a premium of approximately 17.97% over the closing price of H-shares on the Hong Kong Stock Exchange as of the date of this announcement, which was HKD 3.06 per share. The cash consideration will not exceed RMB 493.5 million. The net proceeds will be used to supplement the bank's core Tier 1 capital.
WEIHAI BANK(09677) announced that on December 21, 2025, the bank entered into an H-share subscription agreement with Jinlian Group, intending to issue up to 150 million H-shares to Jinlian Group at a subscription price of RMB 3.29 per share. This represents a premium of approximately 17.97% over the closing market price of HK$3.06 per share on the announcement date on the Hong Kong Stock Exchange. The cash consideration will not exceed RMB 493.5 million. The net proceeds from the fundraising will be used to supplement the bank's core Tier 1 capital.
Related Articles
.png)
IPO news | Keen Gene submits application to Hong Kong Stock Exchange
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.
China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.
IPO news | Keen Gene submits application to Hong Kong Stock Exchange
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.
China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.
